Fig. 1

An RPA-CRISPR-Cas12a platform for the detection of T. vaginalis. a A flow diagram of the RPA-CRISPR-Cas12a detection system in vaginal secretions. DNA extracted from vaginal secretions was preamplified by RPA and mixed with the CRISPR-Cas12a detection system to interpret the results by the fluorescence or lateral flow strip method. b CRISPR-Cas12a activity was determined using the T2 sequence as a target (n = 3 technical replicates; ****p < 0.0001; bars represent the means ± SEM). c Absorbance curves of three purified crRNAs. d Screening of crRNAs for T. vaginalis DNA detection by Cas12a collateral detection (n = 3 technical replicates; *P < 0.05; ***P < 0.001; ****P < 0.0001; bars represent the means ± SEM). e Screening for the best RPA forward primers. f Screening of RPA reverse primers using preferred forward primers